相关实验视频

Updated: Jun 26, 2026

Development of Amelogenin-chitosan Hydrogel for In Vitro Enamel Regrowth with a Dense Interface

Development of Amelogenin-chitosan Hydrogel for In Vitro Enamel Regrowth with a Dense Interface

Published on: July 10, 2014

用于糖尿病伤口包裹的酶模仿酸具有免疫调节和原重塑功能的酶模仿酸

Jiaze Gao¹, Xiaoyang Wu¹, Yucai Hu¹

¹National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, Sichuan 610065, China.

ACS applied materials & interfaces

|June 5, 2025

概括

这项研究引入了一种新的伤口包裹,该包裹集成酸 (HAp) 和铁碳点 (Fe-CDs),通过减少氧化应激和炎症来加速糖尿病伤口愈合.

科学领域:

生物材料科学生物材料科学
再生医学是一种再生医学.
纳米技术纳米技术

背景情况:

糖尿病慢性伤口表现出持续的氧化应激和受损的原重塑,阻碍愈合.
酸 (HAp) 刺激原重塑,而碳点 (CDs) 提供抗炎和抗氧化特性.
现有的伤口通常无法解决糖尿病伤口愈合的复杂多因素性质.

研究的目的:

开发一种新型的伤口包裹,集成HAp和Fe-CDs,以增强糖尿病伤口愈合.
创建一个灵活的,粘合性和功能性的伤口包裹,具有ROS清理和免疫调节能力.
研究开发的包裹在促进组织再生和解决炎症方面的治疗潜力.

主要方法:

通过一阶段的热水方法制造铁合CDs功能化HAp (CDs-HAp).
将CDs-HAp嵌入双交联丝纤维素 (DSF) 水凝中,以形成伤口带 (CDs-HAp@DSF).
在体外 (纤维细胞增殖,原蛋白合成,ROS清理,巨细胞极化) 和体内 (糖尿病伤口愈合模型) 评估带的疗效.

主要成果:

该CDs-HAp@DSF包裹表现出强大的ROS清除和免疫调节功能.
它促进了纤维细胞增殖和原蛋白合成,同时减轻了氧化损伤.
在体内研究显示糖尿病伤口愈合加速,增强原沉积,抑制炎症和重塑免疫微环境.

结论:

开发的CDs-HAp@DSF伤口包裹有效地解决了糖尿病伤口中的氧化应激,炎症和ECM调节障碍.
这种多功能带作为慢性糖尿病伤口愈合的治疗策略具有重大潜力.
矩阵重塑和酶性ROS消除的协同方法为再生医学提供了一个有希望的途径.

关键词:

在ROS清理垃圾.碳点是指碳点的部分.原体重塑的重新塑造糖尿病患者的伤口愈合水凝敷料是一种水凝敷料.氧帕提特是一种氧帕提特.

更多相关视频

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds

Published on: August 21, 2021

Optimizing Extracellular Vesicle Delivery Using a Core-Sheath 3D-Bioprinted Scaffold for Chronic Wound Management

Optimizing Extracellular Vesicle Delivery Using a Core-Sheath 3D-Bioprinted Scaffold for Chronic Wound Management

Published on: February 28, 2025

相关概念视频

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.